Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368680 | 0.81 | FGFR1 (0.55) | SMN1; SMN2MAPTFGFR1LIMK1KDR | |
| SCHEMBL2368440 | 0.78 | MCL1 (0.48) | KDRKMT2AMEN1 | |
| SCHEMBL29689010 | 0.78 | MRGPRX1 (0.59) | SMN1; SMN2MAPTLMNAFGFR1LIMK1 | |
| SCHEMBL6359806 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTLMNAFGFR1LIMK1 | |
| SCHEMBL5792474 | 0.74 | PTGS1 (0.43) | MAPTLMNAADORA3ADORA2AADORA1 | |
| SCHEMBL22320494 | 0.73 | MRGPRX4 (0.37) | FGFR1LIMK1SRCPRKD3MAP4K4 | |
| SCHEMBL14965049 | 0.73 | ALDH1A1 (0.45) | SMN1; SMN2MAPTFGFR1KDRMKNK2 | |
| SCHEMBL2369895 | 0.73 | ATM (0.37) | SMN1; SMN2FGFR1LIMK1SRCPRKD3 | |
| SCHEMBL4765789 | 0.72 | LIMK1 (0.68) | SMN1; SMN2MAPTFGFR1LIMK1SRC | |
| SCHEMBL16815479 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTLMNALIMK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | SMN1; SMN2 3639/4885MAPT 2780/4885LMNA 3153/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | SMN1; SMN2 3669/4885MAPT 2726/4885LMNA 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.